A citation-based method for searching scientific literature


List of co-cited articles
744 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
Samy Hadjadj, Julio Rosenstock, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2016
52
11

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Sophia Zoungas, Hisatomi Arima, Hertzel C Gerstein, Rury R Holman, Mark Woodward, Peter Reaven, Rodney A Hayward, Timothy Craven, Ruth L Coleman, John Chalmers. Lancet Diabetes Endocrinol 2017
183
7

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
182
7

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
83
7

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
119
7


Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Nobuya Inagaki, Shin-Ichi Harashima, Nobuko Maruyama, Yutaka Kawaguchi, Maki Goda, Hiroaki Iijima. Cardiovasc Diabetol 2016
45
13


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
7

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
7

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
921
7

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
252
6


Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Daisuke Yamajuku, Rumi Kihara, Yuka Hayashizaki, Toshiyuki Takasu, Masakazu Imamura, Li Qun, Hiroshi Tomiyama,[...]. Naunyn Schmiedebergs Arch Pharmacol 2012
80
6

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Wenhui Zhang, Walter J J Krauwinkel, James Keirns, Robert W Townsend, Kenneth C Lasseter, Lisa Plumb, Takeshi Kadokura, Fumihiko Ushigome, Ronald Smulders. Clin Drug Investig 2013
17
29

Active sugar transport in health and disease.
E M Wright, B A Hirayama, D F Loo. J Intern Med 2007
400
6

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari, Manabu Ishii, Masaki Sakai, Hideki Kuki, Kenichi Furihata. Clin Drug Investig 2014
22
22

Luseogliflozin: first global approval.
Anthony Markham, Shelley Elkinson. Drugs 2014
49
10

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Damayanthi Devineni, Christopher R Curtin, Thomas C Marbury, William Smith, Nicole Vaccaro, David Wexler, An Vandebosch, Sarah Rusch, Hans Stieltjes, Ewa Wajs. Clin Ther 2015
29
17

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
Muhammad A Abdul-Ghani, Luke Norton, Ralph A Defronzo. Endocr Rev 2011
260
6



Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
6



Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Yutaka Seino, Kohei Kaku, Nobuya Inagaki, Masakazu Haneda, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Endocr J 2015
19
26

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
622
6

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
E Araki, Y Tanizawa, Y Tanaka, A Taniguchi, K Koiwai, G Kim, A Salsali, H J Woerle, U C Broedl. Diabetes Obes Metab 2015
39
12


Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Kazuki Koiwai, Henning Rattunde, Hans J Woerle, Uli C Broedl. Adv Ther 2015
34
14


Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
251
6

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Silvio E Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Jürgen Woerle, Uli C Broedl, Odd Erik Johansen. Diab Vasc Dis Res 2015
247
6

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Eiichi Araki, Yukiko Onishi, Michiko Asano, Hyosung Kim, Ella Ekholm, Eva Johnsson, Toshitaka Yajima. J Diabetes Investig 2016
32
15

Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh, Agata Ptaszynska. Blood Press 2016
59
8

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
57
8




Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Paola Fioretto, Bergur V Stefansson, Eva Johnsson, Valerie A Cain, C David Sjöström. Diabetologia 2016
56
8

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
6

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2015
68
7

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
6

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
224
6


Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
212
6


Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
450
6

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
Melanie J Davies, Stephen C Bain, Stephen L Atkin, Peter Rossing, David Scott, Minara S Shamkhalova, Heidrun Bosch-Traberg, Annika Syrén, Guillermo E Umpierrez. Diabetes Care 2016
92
6



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.